Nicola Xin Yi Koh, Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, Ravindran Kanesvaran, Alvin Seng Cheong Wong, Kenneth Chen, Sue Ping Thang
{"title":"[68Ga] ga - psma - 11pet生物标志物对转移性去势抵抗性前列腺癌[177Lu]Lu-PSMA放射配体治疗的预后影响（亚洲人群研究）。","authors":"Nicola Xin Yi Koh, Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, Ravindran Kanesvaran, Alvin Seng Cheong Wong, Kenneth Chen, Sue Ping Thang","doi":"10.1111/ajco.14174","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Gallium-68 (<sup>68</sup>Ga) prostate-specific membrane antigen (PSMA) ([<sup>68</sup>Ga]Ga-PSMA-11) directed PET/CT reflects PSMA expression at metastatic sites and can hence be a surrogate of lutetium-177 (<sup>177</sup>Lu) PSMA ([<sup>177</sup>Lu]Lu-PSMA) radiation delivery. This retrospective analysis aims to explore the association between quantitative baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET imaging biomarkers and treatment outcomes in our Asian cohort.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We included patients with progressive metastatic castrate-resistant prostate cancer (mCRPC) who received [<sup>177</sup>Lu]Lu-PSMA radioligand therapy at our institution. The association between baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET parameters (SUVmax, SUVmean, total tumor volume [PSMA-TV], total lesion uptake [PSMA-TLU = PSMA-TV × SUVmean], and total lesion quotient [PSMA-TLQ = PSMA-TV / SUVmean]) and overall survival (OS), prostate specific antigen (PSA) progression free survival (PFS), PSA response, and toxicity were analyzed using univariate analysis. Optimal cut-points were also explored.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Between May 9, 2018 and October 7, 2024, 71 of 84 screened patients were eligible. The median whole-body SUVmean in our cohort was 8.04. Higher PSMA-TLQ and PSMA-TV (per 10-unit increment) were associated with shorter OS (HR 1.005; HR 1.005) and shorter PSA PFS (HR 1.005; HR 1.004). A higher PSMA-TLQ was also associated with poorer odds of PSA response (OR 0.994). Conversely, higher SUVmean was associated with longer PSA PFS (HR 0.911) and improved odds of PSA response (OR 1.34). Higher PSMA-TV (per 10-unit increment) and PSMA-TLU (per 100-unit increment) were associated with increased hematological toxicity (OR 1.008; OR 1.012).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>PSMA-TLQ and PSMA-TV were negative prognostic markers and SUVmean was a positive prognostic marker among Asian patients with mCRPC who received [<sup>177</sup>Lu]Lu-PSMA radioligand therapy.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"399-406"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic [68Ga]Ga-PSMA-11 PET Biomarkers for [177Lu]Lu-PSMA Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer (Asian Population Study)\",\"authors\":\"Nicola Xin Yi Koh, Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, Ravindran Kanesvaran, Alvin Seng Cheong Wong, Kenneth Chen, Sue Ping Thang\",\"doi\":\"10.1111/ajco.14174\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>Gallium-68 (<sup>68</sup>Ga) prostate-specific membrane antigen (PSMA) ([<sup>68</sup>Ga]Ga-PSMA-11) directed PET/CT reflects PSMA expression at metastatic sites and can hence be a surrogate of lutetium-177 (<sup>177</sup>Lu) PSMA ([<sup>177</sup>Lu]Lu-PSMA) radiation delivery. This retrospective analysis aims to explore the association between quantitative baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET imaging biomarkers and treatment outcomes in our Asian cohort.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We included patients with progressive metastatic castrate-resistant prostate cancer (mCRPC) who received [<sup>177</sup>Lu]Lu-PSMA radioligand therapy at our institution. The association between baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET parameters (SUVmax, SUVmean, total tumor volume [PSMA-TV], total lesion uptake [PSMA-TLU = PSMA-TV × SUVmean], and total lesion quotient [PSMA-TLQ = PSMA-TV / SUVmean]) and overall survival (OS), prostate specific antigen (PSA) progression free survival (PFS), PSA response, and toxicity were analyzed using univariate analysis. Optimal cut-points were also explored.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Between May 9, 2018 and October 7, 2024, 71 of 84 screened patients were eligible. The median whole-body SUVmean in our cohort was 8.04. Higher PSMA-TLQ and PSMA-TV (per 10-unit increment) were associated with shorter OS (HR 1.005; HR 1.005) and shorter PSA PFS (HR 1.005; HR 1.004). A higher PSMA-TLQ was also associated with poorer odds of PSA response (OR 0.994). Conversely, higher SUVmean was associated with longer PSA PFS (HR 0.911) and improved odds of PSA response (OR 1.34). Higher PSMA-TV (per 10-unit increment) and PSMA-TLU (per 100-unit increment) were associated with increased hematological toxicity (OR 1.008; OR 1.012).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>PSMA-TLQ and PSMA-TV were negative prognostic markers and SUVmean was a positive prognostic marker among Asian patients with mCRPC who received [<sup>177</sup>Lu]Lu-PSMA radioligand therapy.</p>\\n </section>\\n </div>\",\"PeriodicalId\":8633,\"journal\":{\"name\":\"Asia-Pacific journal of clinical oncology\",\"volume\":\"21 4\",\"pages\":\"399-406\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia-Pacific journal of clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14174\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14174","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prognostic [68Ga]Ga-PSMA-11 PET Biomarkers for [177Lu]Lu-PSMA Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer (Asian Population Study)
Aims
Gallium-68 (68Ga) prostate-specific membrane antigen (PSMA) ([68Ga]Ga-PSMA-11) directed PET/CT reflects PSMA expression at metastatic sites and can hence be a surrogate of lutetium-177 (177Lu) PSMA ([177Lu]Lu-PSMA) radiation delivery. This retrospective analysis aims to explore the association between quantitative baseline [68Ga]Ga-PSMA-11 PET imaging biomarkers and treatment outcomes in our Asian cohort.
Methods
We included patients with progressive metastatic castrate-resistant prostate cancer (mCRPC) who received [177Lu]Lu-PSMA radioligand therapy at our institution. The association between baseline [68Ga]Ga-PSMA-11 PET parameters (SUVmax, SUVmean, total tumor volume [PSMA-TV], total lesion uptake [PSMA-TLU = PSMA-TV × SUVmean], and total lesion quotient [PSMA-TLQ = PSMA-TV / SUVmean]) and overall survival (OS), prostate specific antigen (PSA) progression free survival (PFS), PSA response, and toxicity were analyzed using univariate analysis. Optimal cut-points were also explored.
Results
Between May 9, 2018 and October 7, 2024, 71 of 84 screened patients were eligible. The median whole-body SUVmean in our cohort was 8.04. Higher PSMA-TLQ and PSMA-TV (per 10-unit increment) were associated with shorter OS (HR 1.005; HR 1.005) and shorter PSA PFS (HR 1.005; HR 1.004). A higher PSMA-TLQ was also associated with poorer odds of PSA response (OR 0.994). Conversely, higher SUVmean was associated with longer PSA PFS (HR 0.911) and improved odds of PSA response (OR 1.34). Higher PSMA-TV (per 10-unit increment) and PSMA-TLU (per 100-unit increment) were associated with increased hematological toxicity (OR 1.008; OR 1.012).
Conclusion
PSMA-TLQ and PSMA-TV were negative prognostic markers and SUVmean was a positive prognostic marker among Asian patients with mCRPC who received [177Lu]Lu-PSMA radioligand therapy.
期刊介绍：
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
